Damora Therapeutics (DMRA) Equity Average (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Equity Average data on file, last reported at $376.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 2445.64% year-over-year to $376.0 million; the trailing twelve-month figure through Mar 2026 stood at $376.0 million (up 2445.64% YoY), and the FY2025 full-year result was $128.1 million, up 431.98% from the prior year.
• Equity Average for Q1 2026 stood at $376.0 million, up from $124.2 million in the prior quarter.
• Across five years, Equity Average topped out at $376.0 million in Q1 2026 and bottomed at $9.5 million in Q3 2025.
• The 5-year median for Equity Average is $40.5 million (2023), against an average of $68.3 million.
• The widest annual swing landed in 2025, when Equity Average tumbled 57.42%; it then jumped 2445.64% in 2026.
• A 5-year view of Equity Average shows it stood at $67.2 million in 2022, then tumbled by 48.16% to $34.9 million in 2023, then sank by 47.26% to $18.4 million in 2024, then soared by 575.59% to $124.2 million in 2025, then surged by 202.75% to $376.0 million in 2026.
• The last three Equity Average figures came in at $376.0 million (Q1 2026), $124.2 million (Q4 2025), and $9.5 million (Q3 2025), per Business Quant data.

Peer Comparison